Arcutis Biotherapeutics (NASDAQ: ARQT) outlines growth strategy and Q3 2025 results

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. filed a current report to note that it issued a press release on October 28, 2025 outlining its strategy for driving sustainable growth and reporting financial results for the quarter ended September 30, 2025. The company furnished the full press release as Exhibit 99.1, rather than including detailed financial figures in the report itself. The filing clarifies that the press release is being provided for informational purposes and is not considered filed for liability purposes under the securities laws unless specifically incorporated by reference in a future filing.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE000178730600017873062025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

___________________________________________

ARCUTIS BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

___________________________________________

Delaware			001-39186			81-2974255
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

3027 Townsgate Road, Suite300

Westlake Village, CA 91361

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (805) 418-5006

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ARQT

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On October 28, 2025, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release to outline its strategy for driving sustainable growth and to announce its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits

(d)    Exhibits.

Exhibit No.						Description
99.1						Press Release October 28, 2025.
104						Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ARCUTIS BIOTHERAPEUTICS, INC.
			October 28, 2025			By:			/s/ Latha Vairavan
									Latha Vairavan
									Chief Financial Officer

FAQ

What did Arcutis Biotherapeutics (ARQT) disclose in this 8-K?

Arcutis Biotherapeutics reported that it issued a press release on October 28, 2025 outlining its strategy for driving sustainable growth and announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.

Which period do the Arcutis Biotherapeutics (ARQT) financial results cover?

The financial results referenced in the 8-K and related press release cover the quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Arcutis Biotherapeutics (ARQT)?

Detailed results are provided in the company’s October 28, 2025 press release, which is furnished as Exhibit 99.1 to the 8-K.

Is the Arcutis Biotherapeutics (ARQT) press release considered filed for liability purposes?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act unless later specifically incorporated by reference.

Who signed the Arcutis Biotherapeutics (ARQT) 8-K?

The 8-K was signed on behalf of Arcutis Biotherapeutics, Inc. by Latha Vairavan, Chief Financial Officer, on October 28, 2025.